MCID: VGN017
MIFTS: 51

Vaginal Cancer

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Vaginal Cancer

MalaCards integrated aliases for Vaginal Cancer:

Name: Vaginal Cancer 12 53 43 15
Malignant Neoplasm of Vagina 12 33
Vaginal Neoplasms 44 72
Vaginal Malignant Epithelial Tumor 59
Malignant Vaginal Neoplasm 72
Malignant Tumor of Vagina 12
Malignant Vaginal Tumor 12
Neoplasm of Vagina 12
Vaginal Carcinoma 59
Vaginal Neoplasia 72
Vaginal Neoplasm 17
Vagina Carcinoma 72
Vagina Neoplasm 12
Vaginal Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:119
ICD9CM 35 184.0
MeSH 44 D014625
NCIt 50 C3437 C7410
ICD10 33 C52
ICD10 via Orphanet 34 C52
UMLS via Orphanet 73 C0262659
Orphanet 59 ORPHA180247
UMLS 72 C0042237 C0042258 C0262659 more

Summaries for Vaginal Cancer

MedlinePlus : 43 Vaginal cancer is a rare type of cancer. It is more common in women 60 and older. You are also more likely to get it if you have had a human papillomavirus (HPV) infection or if your mother took diethylstilbestrol (DES) when she was pregnant. Doctors prescribed DES in the 1950's to prevent miscarriages. You are also at higher risk if you have had abnormal cells in the vagina, cervix, or uterus. It often doesn't have early symptoms. However, see your doctor if you notice Bleeding that is not your period A vaginal lump Pelvic pain A Pap test can find abnormal cells that may be cancer. Vaginal cancer can often be cured in its early stages. Treatment might include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

MalaCards based summary : Vaginal Cancer, also known as malignant neoplasm of vagina, is related to vaginal carcinosarcoma and vaginal disease, and has symptoms including pelvic pain and vaginal pruritus. An important gene associated with Vaginal Cancer is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways is Antigen Presentation- Folding, assembly and peptide loading of class I MHC. The drugs Octreotide and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include cervix, testes and uterus, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A female reproductive system cancer that is located in the vagina.

Wikipedia : 75 Vaginal cancer is a malignant tumor that forms in the tissues of the vagina. Primary tumors are most... more...

Related Diseases for Vaginal Cancer

Diseases related to Vaginal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Related Disease Score Top Affiliating Genes
1 vaginal carcinosarcoma 11.2
2 vaginal disease 11.1
3 vaginal glandular tumor 11.1
4 vaginal squamous tumor 11.1
5 vagina sarcoma 11.1
6 vaginal yolk sac tumor 11.1
7 vaginal endometrial stromal tumor 11.1
8 malignant germ cell tumor of the vagina 10.4
9 vulvovaginal rhabdomyosarcoma 10.4
10 cervical cancer 10.3
11 squamous cell carcinoma 10.2
12 cervix uteri carcinoma in situ 10.1
13 cervical intraepithelial neoplasia 10.1
14 vulva cancer 10.0
15 in situ carcinoma 10.0
16 endometrial cancer 10.0
17 anus cancer 10.0
18 cystitis 10.0
19 adenocarcinoma 10.0
20 proctitis 10.0
21 vulvar intraepithelial neoplasia 10.0
22 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.9
23 hydronephrosis 9.9
24 squamous cell papilloma 9.9
25 neuroendocrine carcinoma 9.9
26 vaginitis 9.9
27 papilloma 9.9
28 idiopathic interstitial pneumonia 9.9
29 keratinizing squamous cell carcinoma 9.9
30 herpes simplex 9.9
31 rare tumor 9.9
32 leiomyoma 9.8
33 leiomyosarcoma 9.8
34 rectum cancer 9.8
35 clear cell adenocarcinoma 9.8
36 endodermal sinus tumor 9.8
37 rhabdomyosarcoma 9.8
38 embryonal rhabdomyosarcoma 9.8
39 myositis 9.7
40 retinoblastoma 9.7
41 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.7
42 pancreatic cancer 9.7
43 leukemia, acute myeloid 9.7
44 sexual disorder 9.7
45 dermatomyositis 9.7
46 transsexualism 9.7
47 inflammatory spondylopathy 9.7
48 familial retinoblastoma 9.7
49 congestive heart failure 9.7
50 spondylitis 9.7

Comorbidity relations with Vaginal Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Cervical Cancer
Deficiency Anemia Vulva Cancer

Graphical network of the top 20 diseases related to Vaginal Cancer:



Diseases related to Vaginal Cancer

Symptoms & Phenotypes for Vaginal Cancer

UMLS symptoms related to Vaginal Cancer:


pelvic pain, vaginal pruritus

GenomeRNAi Phenotypes related to Vaginal Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.32 MAPK8IP1 MYLK2
2 Decreased viability GR00221-A-1 9.32 MYLK2
3 Decreased viability GR00221-A-2 9.32 MYLK2
4 Decreased viability GR00221-A-4 9.32 MAPK8IP1 MYLK2
5 Decreased viability GR00301-A 9.32 MAPK8IP1
6 Decreased viability GR00342-S-3 9.32 MAPK8IP1
7 Decreased viability GR00402-S-2 9.32 MAPK8IP1 MYLK2

Drugs & Therapeutics for Vaginal Cancer

Drugs for Vaginal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
4
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
5
Ondansetron Approved Phase 3 99614-02-5 4595
6
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
7 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
8 Cola Phase 3
9 Liver Extracts Phase 3
10 Adjuvants, Immunologic Phase 3
11 Antineoplastic Agents, Hormonal Phase 3
12 Analgesics Phase 3
13 Anesthetics, Intravenous Phase 3
14 Narcotics Phase 3
15 Analgesics, Opioid Phase 3
16 Adjuvants, Anesthesia Phase 3
17 Anesthetics, General Phase 3
18 Anesthetics Phase 3
19 DHEA (Dehydroepiandrosterone) Phase 3
20 Immunologic Factors Phase 3
21 Dermatologic Agents Phase 3
22 Neurotransmitter Agents Phase 3
23 Tranquilizing Agents Phase 3
24 Antiemetics Phase 3
25 Anti-Anxiety Agents Phase 3
26 Central Nervous System Depressants Phase 3
27 Gastrointestinal Agents Phase 3
28 Peripheral Nervous System Agents Phase 3
29 Serotonin Antagonists Phase 3
30 Serotonin Agents Phase 3
31 Antipsychotic Agents Phase 3
32 Psychotropic Drugs Phase 3
33 Antipruritics Phase 3
34 Emetics Phase 3
35 Autonomic Agents Phase 3
36 Vaccines Phase 3
37
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
38
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
39
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
40
Indinavir Approved Phase 2 150378-17-9 5362440
41
Mycophenolic acid Approved Phase 2 24280-93-1 446541
42
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
43
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
44
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
45
Fondaparinux Approved, Investigational Phase 2 104993-28-4
46
Bevacizumab Approved, Investigational Phase 2 216974-75-3
47
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
48
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
49
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
50
Durvalumab Approved, Investigational Phase 2 1428935-60-7

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
2 A Randomized Phase III Trial for Evaluation of Usefulness of Pelvic Drains After Radical Hysterectomy and Node Dissection (RHND) Completed NCT00003267 Phase 3
3 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
4 An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds) Completed NCT03158220 Phase 3
5 A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™ Completed NCT01047345 Phase 3
6 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
7 Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa Completed NCT01245764 Phase 3
8 A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women Completed NCT00543543 Phase 3
9 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
12 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 3 Cisplatin;Triapine
13 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Active, not recruiting NCT01536392 Phase 3 Granisetron;Ondansetron
14 A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds) Active, not recruiting NCT00943722 Phase 3
15 Systematic Nutritional Care in Patients Receiving First-line Chemotherapy for Metastatic Gynecologic Cancer in a Phase II Study Unknown status NCT00905658 Phase 2
16 A Phase I/II Feasibility/Efficacy Study of HIFU in Otherwise Untreatable Pelvic Rectal Cancer Unknown status NCT01097239 Phase 1, Phase 2
17 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
18 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
19 EVALUATION OF PACLITAXEL (TAXOL) IN PERSISTENT OR RECURRENT NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX AND VAGINA Completed NCT00002562 Phase 2 paclitaxel
20 A Pilot Study of Conformal Intensity Modulated Radiation Therapy (IMRT) for Gynaecological Cancer Patients Not Suitable for Intracavitary Brachytherapy Boost (GY03.2) Completed NCT00188578 Phase 1, Phase 2
21 Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial Completed NCT00381888 Phase 2 fondaparinux sodium
22 A Phase 2 Study of Triapine® (NSC #663249) and Cisplatin in Combination With Pelvic Radiation for Treatment of Stage IB2-IVa Cervical Cancer or Stage II-IV Vaginal Cancer Completed NCT00941070 Phase 2 triapine;cisplatin
23 A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers Completed NCT00545792 Phase 2 Avastin
24 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
25 A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women Completed NCT00551187 Phase 2
26 Psychosexual Intervention for Gynecologic and Breast Cancer Patients Completed NCT01764802 Phase 2
27 A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies Completed NCT01079832 Phase 2
28 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
29 Effectiveness of an Individualized Symptom Education Program (ISEP) on the Symptom Distress of Women Receiving Radiation for Gynecological Cancer. Completed NCT00275353 Phase 2
30 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
31 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
32 Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer Recruiting NCT03180294 Phase 2 Bupropion Hydrochloride
33 A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers Recruiting NCT03439085 Phase 2
34 A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO) Active, not recruiting NCT01399658 Phase 2
35 A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer Terminated NCT00106262 Phase 2 Velcade (bortezomib);Irinotecan
36 A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn NCT03220009 Phase 2
37 A Phase I Clinical Trial of Intrapleural Adenoviral-Mediated Interferon-beta (IFN-ß) Gene Transfer for Pleural Malignancies Unknown status NCT00066404 Phase 1
38 Phase I Study of Metronomic Daily Dosing of Docetaxel in Women With Progressive or Recurrent Gynecologic Cancer Completed NCT00287885 Phase 1 docetaxel
39 Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies Completed NCT00002949 Phase 1 paclitaxel;vinorelbine tartrate
40 A Phase I Study of Weekly Oral Topotecan in Gynecologic Malignancies Completed NCT00842452 Phase 1 topotecan hydrochloride
41 A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies Completed NCT00523432 Phase 1 Topotecan;CCI-779 (temsirolimus)
42 Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin to Patients With Cancer Predominantly Confined to the Peritoneal Cavity Completed NCT00003548 Phase 1 aminocamptothecin colloidal dispersion
43 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
44 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
45 An Open Label, Sequential Cohort Dose-Escalation Safety, Tolerability and Pharmacokinetic Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma Completed NCT00083213 Phase 1
46 An Open-Label, Long-Term, Safety and Tolerability Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma Completed NCT00082823 Phase 1
47 Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis Completed NCT00003704 Phase 1 capecitabine
48 A Randomized, Double-Blind, Multicenter, Biphasic, Controlled With GARDASIL™ Dose-Escalation Study of Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and ISCOMATRIX™ (IMX) Completed NCT00851643 Phase 1
49 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
50 A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride

Search NIH Clinical Center for Vaginal Cancer

Cochrane evidence based reviews: vaginal neoplasms

Genetic Tests for Vaginal Cancer

Anatomical Context for Vaginal Cancer

MalaCards organs/tissues related to Vaginal Cancer:

41
Cervix, Testes, Uterus, Breast, T Cells, Liver, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Vaginal Cancer:

19
Vagina

Publications for Vaginal Cancer

Articles related to Vaginal Cancer:

(show top 50) (show all 547)
# Title Authors PMID Year
1
Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas. 38 17
30907776 2019
2
Isolated Vaginal Recurrence of Early-Stage Rectal Cancer Detected by 18F-FDG PET/CT. 17
30985425 2019
3
Primary malignant melanoma of the vagina, case report and review of the literature. 17
30764620 2018
4
Use of multifunctional composite nanofibers for photothermalchemotherapy to treat cervical cancer in mice. 38
31290862 2019
5
Total Colpectomy Increases the Risk of Postoperative Hydronephrosis in Vaginal Cancer Patients. 38
29469636 2019
6
Familial Clustering, Second Primary Cancers and Causes of Death in Penile, Vulvar and Vaginal Cancers. 38
31413311 2019
7
Robotic type II B posterior exenteration for recurrent vaginal cancer. 38
31345607 2019
8
Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina. 38
30561092 2019
9
A Systematic Assessment of Google Search Queries and Readability of Online Gynecologic Oncology Patient Education Materials. 38
29353371 2019
10
Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study. 38
30792003 2019
11
Radiation therapy for vaginal cancer in complete uterine prolapse with intrauterine adhesion: a case report. 38
31122220 2019
12
The healthcare costs of treating human papillomavirus-related cancers in Norway. 38
31064346 2019
13
Development and assessment of 3D-printed individual applicators in gynecological MRI-guided brachytherapy. 38
31139221 2019
14
Nail Squamous Cell Carcinoma: A Hidden High-risk HPV Reservoir for Sexually Transmitted Infections. 38
30930083 2019
15
Human Papillomavirus (HPV)-associated Lymphoepithelioma-like Carcinoma of the Vagina and Anal Canal: A Rare Variant of Squamous Cell Carcinoma. 38
29257037 2019
16
Patterns and trends of HPV-related cancers other than cervix in South Africa from 1994-2013. 38
30557819 2019
17
Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. 38
30674687 2019
18
[TNM classification of gynecologic malignancies : What remains to be done beyond 2017?] 38
30707273 2019
19
Importance of Colposcopy Impression in the Early Diagnosis of Posthysterectomy Vaginal Cancer. 38
30418351 2019
20
Severe Vaginal Bleeding in a Case of Renal Cell Carcinoma. 38
31360564 2019
21
Laterally extended endopelvic resection with nephrectomy for vaginal cancer. 38
30454878 2019
22
Definitive Radiotherapy in Invasive Vaginal Carcinoma: A Systematic Review. 38
30139838 2019
23
Gabapentin and Cancer Risk: Updated Findings from Kaiser Permanente Northern California. 38
30939265 2019
24
Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis. 38
30482913 2019
25
Vaginal Dysplasia and HIV: An African American and Caribbean American Cohort Study. 38
30693024 2019
26
Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer. 38
30516621 2018
27
Breast and reproductive cancers in the transgender population: a systematic review. 38
29706033 2018
28
Inversely designed, 3D-printed personalized template-guided interstitial brachytherapy for vaginal tumors. 38
30479625 2018
29
Cancer of the vagina. 38
30306589 2018
30
Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. 38
30054103 2018
31
A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer. 38
30044320 2018
32
The role of FDG-PET/CT in gynecologic imaging: an updated guide to interpretation and challenges. 38
29520427 2018
33
KLK5, a novel potential suppressor of vaginal carcinogenesis. 38
29561728 2018
34
Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina. 38
29929925 2018
35
Perineural Spread Along Spinal and Obturator Nerves in Primary Vaginal Carcinoma: A Case Report. 38
29660549 2018
36
Role of Intraoperative Ultrasound to Extend the Application of Minimally Invasive Surgery for Treatment of Recurrent Gynecologic Cancer. 38
29325966 2018
37
Extraperitoneal Para-Aortic Lymphadenectomy by Robot-Assisted Laparoscopy. 38
29337211 2018
38
Effects of the Affordable Care Act on Young Women With Gynecologic Cancers. 38
29742668 2018
39
Network-based method for mining novel HPV infection related genes using random walk with restart algorithm. 38
29197659 2018
40
Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report. 38
29866134 2018
41
Laparoscopic ovarian transposition prior to pelvic radiation for gynecologic cancer. 38
29915802 2018
42
Image-guided adaptive brachytherapy in primary vaginal cancers: A monocentric experience. 38
29426746 2018
43
Radiotherapy for vaginal cancer: a multi-institutional survey study of the Japanese Radiation Oncology Study Group. 38
29086206 2018
44
Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. 38
29159773 2018
45
The Role of PET Imaging in Gynecologic Radiation Oncology. 38
29482751 2018
46
Primary non-Hodgkin's lymphoma of the vagina: A case report. 38
29556272 2018
47
[Analysis of the factors associated with the long-term curative effect and prognosis of primary vaginal carcinoma]. 38
29575845 2018
48
Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas. 38
29274828 2018
49
Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell Transplantation. 38
29439180 2018
50
Re-irradiation in Gynaecological Malignancies: A Review. 38
29233573 2018

Variations for Vaginal Cancer

Cosmic variations for Vaginal Cancer:

9 (show top 50) (show all 201)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6933523 STAT3 vagina,NS,carcinoma,squamous cell carcinoma c.1110-2A>G p.? 17:42329778-42329778 24
2 COSM6968882 PTPRT vagina,NS,carcinoma,squamous cell carcinoma c.3418G>A p.E1140K 20:42106824-42106824 24
3 COSM6968877 NSD1 vagina,NS,carcinoma,squamous cell carcinoma c.5717G>T p.G1906V 5:177280659-177280659 24
4 COSM6448770 NFKBIA vagina,NS,carcinoma,squamous cell carcinoma c.127G>C p.E43Q 14:35404518-35404518 24
5 COSM6968885 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.415G>T p.E139* 23:20130530-20130530 24
6 COSM6968886 EIF1AX vagina,NS,carcinoma,squamous cell carcinoma c.64G>C p.E22Q 23:20138575-20138575 24
7 COSM6968884 AURKA vagina,NS,carcinoma,squamous cell carcinoma c.127C>T p.Q43* 20:56386449-56386449 24
8 COSM6968887 ATRX vagina,NS,carcinoma,squamous cell carcinoma c.4498G>A p.E1500K 23:77652173-77652173 24
9 COSM6968883 vagina,NS,carcinoma,squamous cell carcinoma c.3382G>A p.E1128K 20:42106824-42106824 24
10 COSM6448769 vagina,NS,carcinoma,squamous cell carcinoma c.127G>C p.E43Q 14:35404518-35404518 24
11 COSM125370 vagina,NS,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 24
12 COSM6968878 vagina,NS,carcinoma,squamous cell carcinoma c.5717G>T p.G1906V 5:177280659-177280659 24
13 COSM6968888 vagina,NS,carcinoma,squamous cell carcinoma c.4498G>A p.E1500K 23:77652173-77652173 24
14 COSM6917051 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4975C>G p.L1659V 16:2086857-2086857 3
15 COSM10662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 3
16 COSM10705 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 3
17 COSM10648 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 3
18 COSM45507 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.806G>C p.S269T 17:7673814-7673814 3
19 COSM43660 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 17:7674244-7674244 3
20 COSM10725 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 17:7674262-7674262 3
21 COSM46185 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 17:7674188-7674188 3
22 COSM10889 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 3
23 COSM43878 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.427G>A p.V143M 17:7675185-7675185 3
24 COSM43624 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.875A>G p.K292R 17:7673745-7673745 3
25 COSM10659 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 3
26 COSM44029 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 17:7675062-7675062 3
27 COSM43896 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.818G>C p.R273P 17:7673802-7673802 3
28 COSM10749 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.830G>T p.C277F 17:7673790-7673790 3
29 COSM43662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 17:7673752-7673752 3
30 COSM11483 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 17:7673772-7673772 3
31 COSM45259 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.301A>T p.K101* 17:7676068-7676068 3
32 COSM11356 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.726C>G p.C242W 17:7674237-7674237 3
33 COSM6917055 TOP1 cervix,NS,carcinoma,squamous cell carcinoma c.1897C>T p.Q633* 20:41118243-41118243 3
34 COSM6933657 TGFBR2 cervix,NS,carcinoma,squamous cell carcinoma c.931G>T p.E311* 3:30672114-30672114 3
35 COSM6918339 TET2 cervix,NS,carcinoma,squamous cell carcinoma c.2659G>A p.E887K 4:105236601-105236601 3
36 COSM6906292 TENT5C cervix,NS,carcinoma,squamous cell carcinoma c.722G>T p.G241V 1:117623590-117623590 3
37 COSM3734673 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.597G>C p.E199D 19:1220505-1220505 3
38 COSM29464 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.169G>T p.E57* 19:1207082-1207082 3
39 COSM25844 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.647C>T p.S216F 19:1220630-1220630 3
40 COSM29465 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.320A>G p.H107R 19:1218446-1218446 3
41 COSM6977087 SPOP cervix,NS,carcinoma,squamous cell carcinoma c.962C>T p.A321V 17:49601883-49601883 3
42 COSM421102 ROS1 cervix,NS,carcinoma,squamous cell carcinoma c.1682C>T p.P561L 6:117389427-117389427 3
43 COSM6977085 RB1 cervix,NS,carcinoma,squamous cell carcinoma c.1630A>T p.R544* 13:48381378-48381378 3
44 COSM6910533 RAD54L cervix,NS,carcinoma,squamous cell carcinoma c.1900C>T p.R634C 1:46277847-46277847 3
45 COSM6977079 RAD50 cervix,NS,carcinoma,squamous cell carcinoma c.432G>C p.E144D 5:132587654-132587654 3
46 COSM6977082 RAD21 cervix,NS,carcinoma,squamous cell carcinoma c.1702C>T p.Q568* 8:116848948-116848948 3
47 COSM6977083 RAD21 cervix,NS,carcinoma,squamous cell carcinoma c.1681C>T p.Q561* 8:116848969-116848969 3
48 COSM6975050 PTPRS cervix,NS,carcinoma,squamous cell carcinoma c.5630C>G p.S1877C 19:5208249-5208249 3
49 COSM6917045 PTPRD cervix,NS,carcinoma,squamous cell carcinoma c.1693G>A p.E565K 9:8504390-8504390 3
50 COSM5089 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.517C>T p.R173C 10:87952142-87952142 3

Expression for Vaginal Cancer

Search GEO for disease gene expression data for Vaginal Cancer.

Pathways for Vaginal Cancer

Pathways related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.02 SAR1B HLA-G

GO Terms for Vaginal Cancer

Cellular components related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ER to Golgi transport vesicle membrane GO:0012507 8.62 SAR1B HLA-G

Biological processes related to Vaginal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 8.62 SAR1B HLA-G

Sources for Vaginal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....